There is the potential for the developed pre-treatment risk prediction tool to provide HER2-positive ABC patients with more realistic expectations of long-term disease control and survival when considering first-line pertuzumab, trastuzumab, and docetaxel therapy. This evidence concerns the gene ERBB2 and aneurysmal bone cyst.